NO20074628L - Formuleringer av octreotid med kontrollert frigjoring - Google Patents

Formuleringer av octreotid med kontrollert frigjoring

Info

Publication number
NO20074628L
NO20074628L NO20074628A NO20074628A NO20074628L NO 20074628 L NO20074628 L NO 20074628L NO 20074628 A NO20074628 A NO 20074628A NO 20074628 A NO20074628 A NO 20074628A NO 20074628 L NO20074628 L NO 20074628L
Authority
NO
Norway
Prior art keywords
controlled release
octreotide
treatment
octreotide formulations
reduction
Prior art date
Application number
NO20074628A
Other languages
English (en)
Norwegian (no)
Inventor
Petr Kuzma
Stephanie Decker
Original Assignee
Indevus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indevus Pharmaceuticals Inc filed Critical Indevus Pharmaceuticals Inc
Publication of NO20074628L publication Critical patent/NO20074628L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20074628A 2005-03-11 2007-09-12 Formuleringer av octreotid med kontrollert frigjoring NO20074628L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66093005P 2005-03-11 2005-03-11
PCT/US2006/008891 WO2006099288A2 (fr) 2005-03-11 2006-03-10 Preparation d'octreotide a liberation lente

Publications (1)

Publication Number Publication Date
NO20074628L true NO20074628L (no) 2007-11-27

Family

ID=36992335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074628A NO20074628L (no) 2005-03-11 2007-09-12 Formuleringer av octreotid med kontrollert frigjoring

Country Status (13)

Country Link
US (8) US7452868B2 (fr)
EP (3) EP1888043A4 (fr)
JP (2) JP4584331B2 (fr)
KR (1) KR101399911B1 (fr)
CN (2) CN103550137B (fr)
AU (4) AU2006223161B2 (fr)
CA (1) CA2601304C (fr)
EA (1) EA015793B1 (fr)
IL (2) IL185800A0 (fr)
NO (1) NO20074628L (fr)
NZ (1) NZ561400A (fr)
UA (1) UA89398C2 (fr)
WO (1) WO2006099288A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858110B2 (en) * 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
CA2437639C (fr) * 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Dispositifs de distribution de medicaments a long terme dotes de polymeres a base de polyurethane et leur fabrication
WO2006009801A2 (fr) 2004-06-17 2006-01-26 Valera Pharmaceuticals, Inc. Compositions et methodes de traitement de la puberte centrale precoce
WO2006065951A2 (fr) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Preparation a liberation continue de composes d'octreotide
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
WO2006099288A2 (fr) * 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Preparation d'octreotide a liberation lente
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
US20080286325A1 (en) * 2006-01-05 2008-11-20 Med Institute, Inc. Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
RU2463079C2 (ru) * 2007-04-27 2012-10-10 Эндо Фармасьютикалз Солюшнз Инк. Разделительные агенты для имплантируемого устройства и способы их применения
US20100196264A1 (en) * 2007-05-18 2010-08-05 The Brigham And Women's Hospital, Inc. Use of somatostatin analogs in myocardial perfusion imaging
WO2009123714A2 (fr) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb>
WO2009148583A2 (fr) * 2008-06-03 2009-12-10 Qlt Usa, Inc. Procédé pour l'amélioration de la biodisponibilité de l'octréotide
US20090325863A1 (en) * 2008-06-13 2009-12-31 Kleinberg David L Somatostatin analogs and IGF-I inhibition for breast cancer prevention
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
EP2317975B1 (fr) 2008-06-25 2016-04-13 Endo Pharmaceuticals Solutions Inc. Implant d'octréotide comportant un agent de libération
RU2678833C2 (ru) 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
KR101707791B1 (ko) 2008-09-30 2017-02-17 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 리스페리돈 전달용 이식형 장치
JP2012504139A (ja) * 2008-09-30 2012-02-16 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． ヒストレリン送達用埋め込み可能型装置およびその使用方法
EP2344122A1 (fr) * 2008-09-30 2011-07-20 Endo Pharmaceuticals Solutions Inc. Dispositif implantable permettant d'administrer de l'octréotide et méthodes d'utilisation correspondantes
JP5864429B2 (ja) 2009-11-09 2016-02-17 スポットライト テクノロジー パートナーズ エルエルシーＳｐｏｔｌｉｇｈｔ Ｔｅｃｈｎｏｌｏｇｙ Ｐａｒｔｎｅｒｓ Ｌｌｃ 架橋ヒドロゲル組成物、ヒドロゲル組成物の形成方法、及びキット
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
WO2012074559A2 (fr) 2010-12-02 2012-06-07 New York University Traitement d'une maladie kystique non proliférative
TWI583401B (zh) 2011-10-24 2017-05-21 布雷本製藥股份有限公司 可植入替紮尼定組合物及其治療方法
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
DK3007704T3 (da) * 2013-06-13 2021-03-29 Antisense Therapeutics Ltd Kombinationsterapi til akromegali
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
JP2016534064A (ja) 2013-10-22 2016-11-04 プロリンクス エルエルシー ソマトスタチン及びその類似体のコンジュゲート
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
PL3242676T3 (pl) 2015-01-07 2024-07-15 Tonix Pharma Limited Preparaty oksytocyny zawierające magnez i sposoby ich stosowania
SI3253401T1 (sl) 2015-02-03 2025-07-31 Amryt Endo, Inc. Zdravljenje akromegalije z oralnim oktreotidom
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
JP2021530568A (ja) 2018-07-19 2021-11-11 ヤモ・ファーマシューティカルズ・エルエルシー 自閉症を処置するための組成物および方法
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US20250152674A1 (en) * 2022-02-25 2025-05-15 Amryt Endo, Inc. Oral octreotide for treatment of disease
AU2024248975A1 (en) * 2023-03-27 2025-11-13 Cellular Longevity, Inc. Pharmaceutical formulations for longevity in mammals
IL328013A (en) * 2023-11-01 2026-06-01 Entrega Inc Oral dosage form with ionically chargeable hydrogel for delivery of active agent and permeation enhancer
WO2026006394A1 (fr) * 2024-06-26 2026-01-02 Loyal Animal Health, Inc. Succédané de somatostatine et compositions et utilisations associées
US20260096905A1 (en) * 2024-10-07 2026-04-09 Pituvia Therapeutics, Inc. Implantable drug-device combinations, and related methods of treatment

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US71736A (en) * 1867-12-03 Improvement in fences
US2168331A (en) 1936-10-17 1939-08-08 Du Pont Cast resin with integral sheen
US2513014A (en) * 1946-11-18 1950-06-27 Abbott Lab Apparatus for implanting medicinal pellets subcutaneously
GB1306541A (en) 1969-01-20 1973-02-14 Ceskoslovenska Akademie Ved Method of manufacturing tubes by centrifugal casting
US3772435A (en) 1971-11-02 1973-11-13 American Cyanamid Co Method of using steroid acetonides as growth promoting agents
US3975350A (en) 1972-08-02 1976-08-17 Princeton Polymer Laboratories, Incorporated Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles
US3921632A (en) * 1974-08-16 1975-11-25 Frank M Bardani Implant device
US4131604A (en) 1977-11-23 1978-12-26 Thermo Electron Corporation Polyurethane elastomer for heart assist devices
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4298002A (en) 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4386039A (en) 1980-02-11 1983-05-31 Thermo Electron Corporation Process for forming an optically clear polyurethane lens or cornea
US4523005A (en) 1981-10-30 1985-06-11 Thermedics, Inc. Extrudable polyurethane for prosthetic devices prepared from a diisocyanate, a polytetramethylene ether polyol, and 1,4-butane diol
US4751133A (en) 1984-11-13 1988-06-14 Thermedics, Inc. Medical patches and processes for producing same
US5342622A (en) * 1986-05-16 1994-08-30 The State Of Victoria Subdermal biocompatible implants
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4743673A (en) 1986-12-19 1988-05-10 Tyndale Plains-Hunter, Ltd. Hydrophilic carboxy polyurethanes
US4871094A (en) 1986-12-31 1989-10-03 Alcon Laboratories, Inc. Means and method for dispensing substances
US4846793A (en) * 1987-03-18 1989-07-11 Endocon, Inc. Injector for implanting multiple pellet medicaments
US4994028A (en) * 1987-03-18 1991-02-19 Endocon, Inc. Injector for inplanting multiple pellet medicaments
AU608891B2 (en) 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US4954587A (en) * 1988-07-05 1990-09-04 Ciba-Geigy Corporation Dimethylacrylamide-copolymer hydrogels with high oxygen permeability
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
HU207940B (en) 1989-02-16 1993-07-28 British Tech Group Feeder apparatus for controlled dissolution of the active components
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5468811A (en) * 1989-11-02 1995-11-21 National Patent Development Corporation Hydrophilic composite polymer articles formed from a settable paste comprising a mixture of hydrophilic polymer and unsaturated monomer
US5254662A (en) 1990-09-12 1993-10-19 Polymedia Industries, Inc. Biostable polyurethane products
US5266325A (en) * 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
AU651654B2 (en) 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
ATE106015T1 (de) * 1990-09-28 1994-06-15 Pfizer Wirkstoffabgabevorrichtung die ein hydrophobisches mittel enthält.
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
AU652984B2 (en) 1992-01-14 1994-09-15 Endo Pharmaceuticals Solutions Inc. Preparation of homogeneous hydrogel copolymers
JP2530079B2 (ja) * 1992-02-05 1996-09-04 ナショナル・パテント・ディベロプメント・コーポレーション 水分膨潤性親水性製品及び薬物放出装置の製造
EP0637323B1 (fr) * 1992-04-24 1998-08-19 The Polymer Technology Group, Inc. Copolymeres et membrane non-poreuse, semi-permeable de ceux-ci, et son utilisation pour filtrer des molecules d'une plage de masses moleculaires predeterminee
US5614223A (en) * 1992-05-04 1997-03-25 Digestive Care Inc. Intraoral medicament-releasing device
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
EP0628959B1 (fr) * 1993-06-11 2000-09-06 Nippon Chemi-Con Corporation Appareil de support et connection d'une tête pour moduler un champ magnétique utilisé pour l'enregistrement photomagnétique
US5354835A (en) 1993-07-23 1994-10-11 Saudi Basic Industries Corporation Desalination process
JPH07252166A (ja) * 1993-09-20 1995-10-03 Shiseido Co Ltd 徐放性製剤
KR950007873A (ko) 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
JPH0797338A (ja) * 1993-09-20 1995-04-11 Shiseido Co Ltd 徐放性製剤
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
CA2264562C (fr) * 1996-08-30 2012-01-03 Peptech Limited Preparation a liberation prolongee d'un peptide
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
AUPO251096A0 (en) 1996-09-23 1996-10-17 Cardiac Crc Nominees Pty Limited Polysiloxane-containing polyurethane elastomeric compositions
US5756127A (en) * 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
JP4798814B2 (ja) * 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
US5854127A (en) * 1997-03-13 1998-12-29 Micron Technology, Inc. Method of forming a contact landing pad
FI971385A0 (fi) 1997-04-04 1997-04-04 Bioxid Oy Biokompatibel komposition, metoder foer dess framstaellning samt anvaendning daerav
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) * 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US6822016B2 (en) 2001-09-10 2004-11-23 Johnson & Johnson Vision Care, Inc. Biomedical devices containing internal wetting agents
AU4992299A (en) * 1998-07-14 2000-02-07 Amylin Pharmaceuticals, Inc. Uncoupling protein 4 (ucp-4) and methods of use
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
US20040071736A1 (en) * 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
JP2002538084A (ja) * 1999-01-14 2002-11-12 アミリン・ファーマシューティカルズ，インコーポレイテッド グルカゴンを抑制する方法
CA2325386C (fr) * 1999-01-28 2010-03-23 Hydromed Sciences A Division Of Gp Strategies Corporation Compositions d'hydrogel utiles pour la liberation prolongee de macromolecules et procedes associes
WO2001051078A1 (fr) * 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et d'agonistes de ces dernieres pour moduler les taux de triglycerides et pour traiter la dyslipidemie
CN1487836A (zh) * 2000-03-14 2004-04-07 埃米林药品公司 胰高糖素样肽1(7-36)对胃窦幽门十二指肠能动性的影响
US6969480B2 (en) * 2000-05-12 2005-11-29 Matregen Corp. Method of producing structures using centrifugal forces
AU2001263230B2 (en) * 2000-05-19 2005-03-10 Amylin Pharmaceuticals, Llc Treatment of acute coronary syndrome with glp-1
JP3498041B2 (ja) * 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
EP2123293A3 (fr) * 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY et agonistes du peptide YY pour le traitement de troubles métaboliques
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
WO2002078597A2 (fr) 2001-04-01 2002-10-10 Yeda Research And Development Co. Ltd. Weizmann Institute Of Science Medicaments a absorption orale
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
US20060122106A1 (en) * 2002-06-14 2006-06-08 Amylin Pharmaceuticals, Inc Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
US6942264B1 (en) * 2003-02-10 2005-09-13 Richard Mendez Disposable pet waste receptacle
CA2437639C (fr) * 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Dispositifs de distribution de medicaments a long terme dotes de polymeres a base de polyurethane et leur fabrication
WO2005041873A2 (fr) 2003-10-24 2005-05-12 Azopax Therapeutics Llc Formulation de l'exendine-4
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2006009801A2 (fr) * 2004-06-17 2006-01-26 Valera Pharmaceuticals, Inc. Compositions et methodes de traitement de la puberte centrale precoce
SE0402345L (sv) * 2004-09-24 2006-03-25 Mederio Ag Uppmätt läkemedelsdos
WO2006099288A2 (fr) 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Preparation d'octreotide a liberation lente
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US20070037897A1 (en) 2005-08-12 2007-02-15 Guigui Wang Method for making contact lenses
JP2009507050A (ja) 2005-09-08 2009-02-19 ガストロテック・ファルマ・アクティーゼルスカブ 胆道ジスキネジーおよび／または胆道痛／不快の治療のためのｇｌｐ−１分子の使用
WO2008061355A1 (fr) 2006-11-24 2008-05-29 Matregen Corp. Systèmes de dépôt de glp-1, et leurs procédés de fabrication et utilisations
RU2463079C2 (ru) 2007-04-27 2012-10-10 Эндо Фармасьютикалз Солюшнз Инк. Разделительные агенты для имплантируемого устройства и способы их применения
EP2317975B1 (fr) * 2008-06-25 2016-04-13 Endo Pharmaceuticals Solutions Inc. Implant d'octréotide comportant un agent de libération

Also Published As

Publication number Publication date
US20200046806A1 (en) 2020-02-13
WO2006099288A2 (fr) 2006-09-21
US8507432B2 (en) 2013-08-13
AU2006223161B2 (en) 2011-05-12
CA2601304C (fr) 2010-08-17
NZ561400A (en) 2010-02-26
WO2006099288A3 (fr) 2007-03-01
KR101399911B1 (ko) 2014-06-19
AU2006223161A1 (en) 2006-09-21
AU2011201457B2 (en) 2011-05-19
IL214617A (en) 2016-05-31
AU2011201460A1 (en) 2011-04-21
EP2455072A1 (fr) 2012-05-23
IL214617A0 (en) 2011-09-27
AU2011201457A1 (en) 2011-04-21
CN103550137B (zh) 2015-07-29
CA2601304A1 (fr) 2006-09-21
AU2011201460B2 (en) 2011-07-28
JP2010189401A (ja) 2010-09-02
JP4584331B2 (ja) 2010-11-17
UA89398C2 (uk) 2010-01-25
US7452868B2 (en) 2008-11-18
US20060204540A1 (en) 2006-09-14
IL185800A0 (en) 2008-01-06
KR20080005496A (ko) 2008-01-14
US7803773B2 (en) 2010-09-28
EP1888043A4 (fr) 2010-07-28
US20090087470A1 (en) 2009-04-02
CN101193626A (zh) 2008-06-04
EP1888043A2 (fr) 2008-02-20
US20250255936A1 (en) 2025-08-14
US20170100461A1 (en) 2017-04-13
JP2008533046A (ja) 2008-08-21
EA015793B1 (ru) 2011-12-30
EA200701956A1 (ru) 2008-02-28
US20200353055A1 (en) 2020-11-12
CN103550137A (zh) 2014-02-05
US20110009338A1 (en) 2011-01-13
EP2457564A1 (fr) 2012-05-30
AU2011201471B2 (en) 2011-05-19
US20100317579A1 (en) 2010-12-16
AU2011201471A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
WO2006099288A3 (fr) Preparation d&#39;octreotide a liberation lente
WO2004052847A3 (fr) Modulateurs tricycliques du recepteur nucleaire des hormones steroidiennes
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
WO2005069933A3 (fr) Procedes permettant de traiter une maladie de type inflammatoire
WO2005115361A3 (fr) Modulateurs des recepteurs d&#39;androgenes et methodes de traitement de maladies utilisant ceux-ci
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
NO20081889L (no) Fast vaksine formulering
DE60332629D1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate
MXPA05008617A (es) Usos de anticuerpos anti-receptor del factor de crecimiento semejante a la insulina i.
CA3094580A1 (fr) Formulations orales d&#39;analogues de cytidine et leurs procedes d&#39;utilisation
SE0101379D0 (sv) Komposition som hämmar utsöndring av magsyra
WO2003097052A3 (fr) Methodes et compositions faisant appel a des composes immunomodulateurs pour le traitement et la prise en charge des cancers et d&#39;autres maladies
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
WO2005009370A3 (fr) Composes de beta-carboline ainsi que leurs analogues et leur utilisation en tant qu&#39;inhibiteurs de proteine kinase-2 activee par proteine kinase activee par des mitogenes
AR048431A1 (es) Formulaciones galenicas de compuestos organicos
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
WO2006124447A3 (fr) N-arylpyrrolidines substituees utilisees comme modulateurs selectifs du recepteur des androgenes
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
NO20074175L (no) Fremgangsmater for kontroll av QT-intervall
WO2003079991A3 (fr) Technique d&#39;administration d&#39;hormone de croissance par voie pulmonaire
WO2007048220A3 (fr) Composition de trazodone a administration quotidienne
NO20075393L (no) Akarbosebaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse
WO2008100448A3 (fr) Procédé de traitement des troubles prolifératifs cellulaires utilisant un sécrétagogue d&#39;hormone de croissance
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d&#39;utilisation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application